文献速递肝病

NAFLD相关肝硬化患者治疗的当前挑战与未来展望

Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
PubMed 文献 · Hepatology · 2023-05-16

尽管NAFLD进展缓慢,NAFLD相关肝硬化患者数量显著增加。本综述基于科学学会推荐意见,批判性讨论NAFLD相关肝硬化患者管理的特殊性,涵盖减重策略、代谢合并症控制、减重手术、门静脉高压诊治及药物研发与临床试验的困难,并讨论克服这些障碍的新兴选择。

要点

  • NAFLD相关肝硬化管理需兼顾肝脏、代谢与心血管疾病,治疗应同时针对肝脏及 cardiometabolic 状况。
  • 减重生活方式干预需避免肌少症并改善门静脉高压;口服降糖药在肝硬化中的安全性是讨论重点。
  • 肝硬化患者行减重手术面临门静脉高压及肝硬化失代偿风险;NAFLD相关肝硬化药物研发与临床试验存在困难。

核心结论

  • NAFLD相关肝硬化患者预后改善面临挑战,因其处于肝脏、代谢与心血管疾病的交叉点,治疗干预应同时针对肝脏及 cardiometabolic 状况并相应调整。

研究设计与样本

  • 本综述基于科学学会的推荐意见,在NAFLD肝硬化的特定背景及周围 cardiometabolic 环境中进行批判性讨论。

主要发现

  • 综述覆盖以下方面:通过生活方式干预减重以避免肌少症并改善门静脉高压;优化代谢合并症控制特别是2型糖尿病以改善心血管发病率/死亡率并降低肝硬化相关并发症发生率;肝硬化患者行减重手术的挑战与门静脉高压及肝硬化失代偿风险相关;门静脉高压诊断与管理的特殊性及等待肝移植患者的管理困难;NAFLD相关肝硬化药物研发与临床试验的困难;并讨论克服这些障碍的新兴选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the slow, progressive nature of NAFLD, the number of patients with NAFLD-related cirrhosis has significantly increased. Although the management of patients with cirrhosis is constantly evolving, improving the prognosis of patients with NAFLD-related cirrhosis is a challenge because it is situated at the crossroads between the liver, the metabolic, and the cardiovascular diseases. Therefore, the therapeutic interventions should not only target the liver but also the associated cardiometabolic conditions and should be adapted accordingly. The objective of the current review is to critically discuss the particularities in the management of patients with NAFLD-related cirrhosis. We relied on the recommendations of scientific societies and discussed them in the specific context of NAFLD cirrhosis and the surrounding cardiometabolic milieu. Herein, we covered the following aspects: (1) the weight loss strategies through lifestyle interventions to avoid sarcopenia and improve portal hypertension; (2) the optimal control of metabolic comorbidities in particular type 2 diabetes aimed not only to improve cardiovascular morbidity/mortality but also to lower the incidence of cirrhosis-related complications (we discussed various aspects related to the safety of oral antidiabetic drugs in cirrhosis); (3) the challenges in performing bariatric surgery in patients with cirrhosis related to the portal hypertension and the risk of cirrhosis decompensation; (4) the particularities in the diagnosis and management of the portal hypertension and the difficulties in managing patients awaiting for liver transplantation; and (5) the difficulties in developing drugs and conducting clinical trials in patients with NAFLD-related cirrhosis. Moreover, we discussed the emerging options to overcome these obstacles.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mallet M, Silaghi CA, Sultanik P, et al. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology. 2023. PMID: 37183906. doi:10.1097/HEP.0000000000000456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。